We determined previously that LSD1 was more highly expressed in metastatic castration-resistant prostate cancer (CRPC) progressing on androgen-lowering treatments — the vast majority of which were adenocarcinomas — versus localized prostate cancer (13). Here, KDM1A is linked to adenocarcinoma.